Mink Therapeutics Investor Relations Material

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T cell therapies for the treatment of cancer and other immune-mediated diseases. Our lead product candidate, MM-111, is an investigational iNKT cell receptor agonist being studied in several ongoing clinical trials in Japan and the United States. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.